Nuvation Bio (NUVB) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xencor (XNCR) has outperformed Nuvation Bio (NUVB) over the past year, gaining 97.6% versus a gain of 33.1%. Over five years, XNCR leads with a -36.3% price change compared with -48.2% for NUVB. Xencor is the larger company by market cap ($1.83 billion vs $1.76 billion), about 1.0 times the size, while Nuvation Bio is growing revenue faster (+699.0% vs +13.7%).
Xencor converts more of its revenue into profit, with a net margin of -73.2% versus -325.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NUVB | XNCR |
|---|---|---|
| Share price | $5.00 | $24.63 |
| Market cap | $1.76B | $1.83B |
| 1-day change | +1.01% | +0.53% |
| YTD return | -44.75% | +60.03% |
| 1-year return | +33.06% | +97.58% |
| 5-year return | -48.17% | -36.31% |
| EPS (TTM) | $-0.44 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $62.90M | $125.58M |
| Revenue growth (YoY) | +698.96% | +13.65% |
| Net income (latest FY) | $-204.63M | $-91.92M |
| Operating margin | -338.72% | -141.35% |
| Net margin | -325.31% | -73.20% |
| 52-week high | $9.75 | $30.61 |
| 52-week low | $3.36 | $10.38 |
| Distance from 52-week high | -48.72% | -19.54% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +160.00% | +27.57% |
| Average volume | 5.65M | 1.32M |
| Shares outstanding | 350.12M | 74.35M |
| Employees | 305 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed NUVB by 64.5 percentage points over the past year.
- Xencor is more profitable, keeping -73.2 cents of every revenue dollar as net income versus -325.3 cents for Nuvation Bio.
- Nuvation Bio grew revenue faster in its latest fiscal year (+698.96% vs +13.65%).
About Nuvation Bio
NUVB stock →Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 305 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
NUVB vs XNCR FAQ
Which is bigger, Nuvation Bio or Xencor?
Xencor (XNCR) is larger, with a market capitalization of $1.83B compared with $1.76B for Nuvation Bio (NUVB).
Which stock has performed better over the past year, NUVB or XNCR?
XNCR returned +97.58% over the past 12 months, compared with +33.06% for NUVB (price return, excluding dividends). Past performance does not predict future results.
Are Nuvation Bio and Xencor in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.